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Abstract 
Background: Propofol is commonly used for providing sedation in 
endoscopic retrograde cholangiopancreatography (ERCP). It’s simple to use 
and effective but presents cardiovascular and respiratory adverse effects. 
Recently, dexmedetomidine has been tried but very little evidence exists to 
support its use. The aim of this study was to compare the efficacy and safety 
of combination of dexmedetomidine and lidocaine (DL) with the standard 
propofol-fentanyl (PF) regimen. 
Materials and Methods: After approval of the hospital ethics committee, 63 
patients (18-60 years of age) were randomly divided into 2 groups. Thirty-one 
patients received a PF combination (group PF), and 32 patients received DL 
combination (group DL). The level of sedation was adjusted to achieve a 
Ramasy Sedation Scale (RSS) score of 3 (moderate sedation) in both groups 
of patients. Arterial pressure (MAP), heart rate (HR), and peripheral oxygen 
saturation (SpO2) during ERCP and recovery was continuously assessed. 
Results: The oxygen saturation (SpO2) showed high statistical significant 
differences between both groups throughout the procedure with stability in 
DL group (p<0.01). There was no statistical difference in HR and MAP 
between the two groups (p>0.05). Post-procedural recovery time was 
significantly shorter in PF group (15.97±3.27 min) compared with 
(19.38±5.64 min) DL group (p<0.01). PONV was 3.2% in PF group, while 
it was absent in DL group. No drug adverse effect or cardiovascular 
complications were observed in both groups. 
Conclusion: Dexmedetomidine and lidocaine combination as total 
intravenous anesthesia (TIVA) during ERCP not only did not reported any 
oxygen desaturation (SpO2<90%) but also showed better stability of oxygen 
saturation (SpO2) and less PONV when compared with propofol and fentanyl 
combination. 
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pancreatography (ERCP) has revolutionized the 
management of many pancreatic and biliary problems 
with its utility ranging from a diagnostic solution to 
complex diagnosis and therapeutic intervention (1, 2). 
It is a complex procedure which requires technical 
expertise as well as adequate sedation and anesthesia. 
The procedure time ranges from 30 to 60 minutes, and 
it is performed with the patient in the prone or semi-
prone position. Moderate to deep levels of sedation 
and analgesia are required to minimize patient 
discomfort and to facilitate the operation (3).  
ERCP is a complicated and long procedure. It 
requires moderate to deep sedation, and even general 
anesthesia. The level of sedation depends on the type 
of ERCP procedure as diagnostic or therapeutic and 
patient characteristics (4-6). There are various agents 
available to provide sedation. Current drugs include 
benzodiazepines (7) with an opioid; most commonly 
midazolam and diazepam (8), with or without 
propofol often combine with fentanyl or remifentanil 
(9). Ketamine has also been used in low doses for 
moderate sedation. Newer agents such as 
dexmedetomidine (10) and fospropofol are also being 
used (11). Combination with Lidocaine never been 
used. The anti inflammatory and analgesic properties 
of Lidocaine has also shown in new studies (29). 
Recently dexmedetomidine has been used as 
TIVA in conscious sedation. A few studies have 
reported the success of dexmedetomidine in 
combination with ketamine and propofol as safe and 
effective sedative agent (12, 13). PF-based sedation 
techniques are effective for ERCP procedures but are 
not without cardiovascular and respiratory adverse 
effects (13). The use of dexmedetomidine as the sole 
anesthetic agent and as the 
adjuvantanalgesicagenthasbeenpublishedbuthasnotbee
neffective as propofol combined with fentanyl for 
conscious sedation during ERCP (14). This study was 
designed to compare the efficacy and safety profile of 
dexmedetomidine-lidocaine (DL) combination with 
the standard propofol and fentanyl (PF). 
Methods 
This study was approved by the ethics 
committee of Shahid Beheshti University of Medical 
Sciences at the Taleghani Hospital. The sample was 
drawn from patients admitted to undergo ERCP. We 
excluded patients who had ASA physical status Grade 
III and more, baseline SpO2<90%, mechanically 
ventilated patients, patients with comorbid conditions 
such as diabetes mellitus, hypertension (HTN) or 
hepatic or renal insufficiency to see the pure effect of 
both these drugs and to avoid any interaction with any 
simultaneous drug intake, which could have altered 
the results. Sixty-three patients with American 
Society of Anesthesiologist (ASA) classification I and 
II, aged 18 to 60 years, admitted for diagnostic and 
therapeutic ERCPs, were enrolled in the study. 
Patients provided written informed consent for 
participation in the study.  
A detailed pre-operative check-up including 
general examination and systemic examination of the 
patient was carried out. On arrival in the Endoscopy 
Room, all vital parameters such as heart rate (HR), 
systolic blood pressure (SBP), diastolic blood 
pressure (DBP), mean arterial pressure (MAP) and 
oxygen saturation (SpO2) were recorded. Readings 
were taken following the loading dose and every 5 
min until the completion of the procedure.  
This randomized, blind double-dummy clinical 
trial, with the rater blinded to the intervention, was 
conducted with patients who were undergoing an 
ERCP. The intervention was in the form that one 
group of patients was given dexmedetomidine with 
lidocaine (DL) and other group received propofol 
with fentanyl (PF) until achieving Ramasy sedation 
scale (RSS) score to 3 or 4 as moderate to deep 
sedation (Table 1). The DL group (n=32) received 
dexmedetomidine; (200 µg/ 2 ml) which prepared as 
2 ml plus 48 ml normal saline total volume 50 ml. 
patients received loading dose of 1 µg/kg intravenous 
over 10 min and in 7 min lidocaine 1.5 ml/kg and then 
followed by 0.5 µg/kg/h infusion until RSS reached to 
3-4. Group PF (n=31) received a single dose of 
midazolam (1mg) and additional fentanyl 1µg/kg and 
after 2 min patient received propofol 1 µg/kg/h in 60 
sec and the followed by0.5 µg/kg/h infusion until RSS 
reached to 3-4. We used these doses of propofol and 
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dexmedetomidine to preserve sufficient consciousness 
to allow communication, but provided the necessary 
degree of sedation to enable surgical comfort and an 
adequate quality of recovery with no negative effects 
on hemodynamics and respiratory parameters. 
The drug infusion was discontinued if one of 
the following adverse events was observed: 
hemodynamic and/or respiratory instability, i.e., 
hypotension (mean arterial pressure reduction of 30% 
of its initial value), or apnea longer than 30 seconds, 
or oxygen desaturation<90%. During the procedure, 
any of the following complications were noted, 
recorded and treated accordingly: oxygen desaturation 
was considered when SpO2 less than 90% for more 
than 10s. Both groups were managed by supporting 
airway and/or assisting ventilation. Bradycardia was 
considered when HR was less than 50 beats/min and 
managed with atropine 20 mcg/kg intravenous 
Hypotension was considered when MAP decreased by 
>20% of the baseline MAP and managed by fluid 
bolus or vasopressors. Any cough or gagging was 
noted and recorded. 
Outcome assessed 
The primary outcome was defined as the 
sedation level recorded by the RASS and the 
requirement of additional sedatives or an analgesic to 
display signs of insufficient analgesia. The level of 
sedation was judged adequate when the score on 
RASS was above or equal to 3, whether the patient 
tolerated the introduction of the endoscope without 
the presence of pain, discomfort, or agitation. The 
secondary outcome was the respiratory maintenance 
pattern, which was assessed by oxygen saturation 
(SpO2).Furthermore, the HR and mean arterial 
pressure (MAP) were measured by the automated 
oscillography method. The SpO2 was monitored by a 
finger probe. The HR, MAP and SpO2 were 
continuously monitored and recorded at 5 min 
interval. Postoperative nausea and vomiting (PONV) 
were recorded and managed accordingly. Times of 
induction, procedure, recovery, and adverse effects 
were also reported. 
Statistical analysis 
Data were entered and analyzed using 
statistical package for social sciences (SPSS) for 
windows version 21 software (SPSS Inc., Chicago, 
IL, USA). Data were statistically described in terms 
of mean± standard deviation (±SD), or frequencies 
(number of cases) and percentages when appropriate. 
Numerical data between both groups were done using 
Student’s t-test or Mann-Whitney test, depending on 
the distribution for independent samples. Categorical 
data were compared by Chi-square test with 
continuity correction or Fisher's exact test as 
applicable. P values less than 0.05 were considered 
statistically significant. 
Results 
The study recruited 64 patients scheduled for 
ERCP over a period of 6 months at a single 
institution. They were randomized into 2 groups, PF 
and DL, with 32 patients in each. The data were 
collected from 32 patients in group DL and 31 
patients in group PF. One patient from group PF was 
excluded from the study because of missing data or 
procedure termination due to unrelated sedation 
reasons. Patient characteristics in two groups were 
shown in table 2. There were no significant 
differences in the demographic characteristics data 
between the two groups.  
 
Figure 1.(A) Lidocaine Formula; (B) Dexmedtomidine Formula. 
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HR, MAP, SpO2, recovery time and POVN 
were given as mean±SD in Table 3. Patients in DL 
group significantly showed more stability of SpO2 
than patients in PF group (p=0.002).There were no 
significant differences in MAP and HR values 
between the two groups (p>0.05). Recovery times 
were significantly longer in the DL group (p=0.011). 
Nausea and Vomiting (PONV) were observed in one 
patient (3.2%) in group PF, while it was absent in DL 
group but there were no significant statistically 
Table 4: Changes of HR between two groups during the ERCP procedure. 
 
HR Group DL (n=32) Group PF (n=31) P-value 
Time Variable 
(min) 
Mean±SD Range  
(min-Max) 
Mean±SD Range  
(min-Max) 
 
First 86.25±11.29 70-120 82.26±14.54 65-110 0.220 
0-5 86.81±11.29 70-110 82.74±13.77 65-115 0.136 
5-10 84.06±9.95 70-105 79.81±14.43 60-120 0.082 
10-15 82.41±11.45 70-105 77.58±12.84 60-105 0.144 
15-20 81.09±10.91 65-110 76.94±12.29 60-105 0.128 
20-25 79.22±9.85 65-110 76.61±10.98 55-100 0.395 
25-30 77.81±8.03 65-90 76.29±10.72 60-100 0.292 
30-35 75.16±8.93 60-95 76.13±10.22 55-100 0.692 
35-40 75.94±8.65 60-95 77.26±9.56 65-100 0.715 
Total 80.31±9.88 60-120 77.92±11.85 55-120 0.341 
 
Group DL; dexmedetomidine with lidocaine, group PF; propofol with fentanyl, P-value<0.05 was considered statistically 
significant 
Table 1: Ramsay Sedation Scale. 
 
Score Term Description 
1 Drowsy Not fully alert but has sustained awakening (eye opening) to voice (>10s) 
2 Light sedation Briefly awakens with eye contact to voice (< 10s) 
3 Moderate sedation Movement or eye opening to voice (but not eye contact) 
4 Deep sedation Not responsive to voice but movement or eye opening to physical stimulation  
5 Unarusable No response to voice or physical stimulation 
 
 
Table 2: Characteristics of patients in two groups (n=63). 
 
Variables Group DL (n=32) Group PF (n=31) P-value 
Gender (M/F) 19/13 17/14 0.716 
Age 51.91±5.96 49.16±8.73 0.152 
ASA type (I/ II) 19/13 18/13 0.916 
Smoker 7 (21.9%) 13 (41.9%) 0.087 
 
Data were expressed as mean±SD. P value> 0.05 was considered statistically not significant. Group DL; dexmedetomidine with 
lidocaine, group PF; propofol with fentanyl. ASA; American Society of Anesthesiologists 
Table 3: Vital sign during ERCP and recovery time. 
 
Variables Group DL (n=32) Group PF (n=31) P-value 
HR  (beat/min) 80.31±9.88 77.92±11.85 0.341 
MAP (mm Hg) 78.02±5.43 77.86±7.31 0.738 
Spo2 96.02±1.55 94.54±3.01 0.002* 
Recovery time 19.38±5.64 15.97±3.27 0.011* 
PONV 0 (0) 1 (3.2%) 0.492 
 
HR: Heart rate, MAP: Mean arterial pressure, Spo2: Oxygen saturation, PONV: Postoperative nausea-vomiting, P-value<0.05 was 
considered statistically significant 
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(p=0.492). there was no event of drug adverse or 
cardiovascular complication observed in both 
regimens.  
There were no significant differences in HR 
and MAP between two groups after loading dose in 
5,10,15,20,25,30,35 and 40 min during ERCP 
procedure (Table 4 and 5). The case of oxygen 
desaturation (SpO2 <90%) was observed in PF groups 
after the loading dose at 5 to 35 minutes during ERCP 
procedure. While, it was absent in DL group and no 
cases in this group presented oxygen desaturation 
(SpO2 <90%). There is a significant difference in the 
Table 5:Changes of MAP between two groups during the ERCP procedure. 
 








First 82.97±4.37 75-95 81.94±4.60 70-90 0.717 
0-5 81.41±5.42 70-95 81.61±5.23 70-95 0.947 
5-10 80.19±6.68 65-100 80.48±6.63 70-100 0.861 
10-15 79.00±6.96 60-95 78.06±9.10 60-100 0.431 
15-20 77.81±6.59 60-95 75.64±7.61 60-95 0.098 
20-25 76.56±4.99 60-90 75.48±7.46 65-100 0.158 
25-30 76.56±4.99 70-90 76.45±7.09 70-100 0.477 
30-35 76.09±3.75 70-80 76.94±8.03 65-100 0.828 
35-40 76.56±4.10 70-85 78.23±7.37 65-100 0.415 
Total 78.02±5.43 60-100 77.86±7.31 60-100 0.738 
 
Group DL; dexmedetomidine with lidocaine, group PF; propofol with fentanyl, P-value<0.05 was considered statistically 
significant 
Table 6: Changes of SpO2 between two groups during the ERCP procedure. 
 








First 96.53±1.74 99-100 96.26±1.29 94-99 0.401 
0-5 96.13±1.74 93-100 95.81±1.70 92-99 0.465 
5-10 96.16±1.71 93-99 94.87±3.06 88-99 0.274 
10-15 96.16±1.72 92-99 93.81±4.26 85-98 0.064 
15-20 96.03±1.69 92-99 93.39±4.24 86-98 0.032 
20-25 96.09±1.42 92-99 93.29±3.58 86-98 0.006 
25-30 95.94±1.56 92-99 94.06±2.87 88-98 0.015 
30-35 95.78±1.36 93-98 95.23±2.67 86-98 0.809 
35-40 95.94±1.27 93-98 95.87±1.75 92-99 0.849 
Total 96.02±1.55 92-100 94.54±3.01 85-99 0.002 
 
Group DL; dexmedetomidine with lidocaine, group PF; propofol with fentanyl, P-value<0.05 was considered statistically 
significant 
 
Figure 1.HR during the procedure between two groups. 
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oxygen saturation (SpO2) level between the two 
groups in the 15, 20 and 25 minute of ERCP process 
(p=0.03, p=0.006 and p=0.015) respectively. Patients 
in DL group significantly showed more stability 
(p=0.002) of SpO2 after the loading dose at 5, 10, 15, 
20, 25, 30, 35 and 40 min during ERCP procedure 
(Table 6).  
Figures 1 to 3;HR (beats/min), MAP (mmHg), 
and SpO2 (as Mean±SD), determined at different 
stages of the study, including baseline (at least 5 
minutes before the first drug administration), 5, 10, 
and 15 minutes after starting sedation, and from 15 
minutes until the end of an ERCP (40 min). 
Discussion 
The goals of this study were to provide 
adequate steady state of sedation level while 
maintaining airway reflex, maintain cardiovascular 
and respiratory status, minimize side effects and pain 
and ensure patient comfort. Generally, propofol alone 
or in combination with midazolam or fentanyl is one 
of the most widely used regimens for sedation during 
the ERCP (15-17).However, the combination use of 
sedatives with propofol may produce some additional 
risks (9, 18). In this study we compared the efficacy 
and safety of two different methods of moderate 
sedation; we used dexmedetomidine and lidocaine 
combination (DL) versus propofol and fentanyl 
combination (PF) during ERCP procedure. 
Many previous studies use dexmedetomidine in 
combination or single as anesthetic agent during 
ERCP procedure and they reported different results. 
Eldesuky Ali Hassan et al. compared the 
hemodynamic stability, respiratory effect and 
recovery time in patient, who were randomly assigned 
in the two groups. Group D received 
dexmedetomidine as single aesthetic agent, and group 
K received a combination of ketamine and propofol 
(Ketofol) as aesthetic agent. MAP and HR in group D 
were significantly lesser than in the ketofol group. 
Additionally, time to achieve RSS score and total 
dose of rescue sedation in both groups were not 
significantly different. However, patient and 
endoscopist satisfaction in the ketofol group was 
significantly higher than in the dexmedetomidine 
group (4). Furthermore, Ceylan et al. (19) used 
dexmedetomidine (D) as single aesthetic agent and 
 
Figure 2.MAP during the procedure between two groups. 
 
Figure 3.SpO2 during the procedure between two groups. 
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then evaluated the effects of propofol and 
dexmedetomidine hemodynamics stability and 
satisfaction during ERCP procedure. The fifty 
patients with ASA physical status class Ⅰ and Ⅱ were 
randomized into the two groups. Group P and group 
D received propofol and dexmedetomidine 
respectively. All patients were sedated to attain a RSS 
of 3-4. The mental status examination before and after 
the procedure as well as pain was evaluated. The 
blood pressure and heart rate values in group D were 
significantly lesser than in group P. However, there 
were no significant differences in patient and 
endoscopist satisfaction among the two groups.  
In combination form of dexmedetomidine, the 
efficacy of dexmedetomidine with propofol for 
anesthesia in ERCP procedure was evaluated by 
Abdalla et al. (20). Sixty patients with ASA physical 
status class Ⅱ or Ⅲ underwent ERCP procedures were 
randomly assigned into two groups. Group DF 
received combination of dexmedetomidine and 
propofol, group K, patients received a loading dose of 
ketamine 1 mg/kg and followed by 0.5 mg/kg per 
hour. Group DF during ERCP procedure showed 
better hemodynamic stability, less nausea and 
vomiting, as well as shorter recovery time when 
compared with the combination of ketamine and 
propofol. However, the negative results of the use of 
dexmedetomidine for ERCP procedure have been 
reported; for example, the study of Nagaraj et al. (21) 
compared the combination of dexmedetomidine and 
fentanyl with the combination of propofol and 
fentanyl for procedural sedation in ERCP procedure. 
The result of study showed that the combination of 
propofol and fentanyl achieved better overall 
conditions for ERCP compared to the combination of 
dexmedetomidine and fentanyl. Other studies used of 
dexmedetomidine with ketamine or propofol 
combination for sedation in ERCP procedures and 
reported that combination of dexmedetomidine gives 
more respiratory safety and hemodynamic stability 
(22, 23). The most of studies used dexmedetomidine 
with ketamine or propofol combination as induction 
agent for moderate to deep sedation but no study used 
it with lidocaine combination. 
Therefore, in this study we used 
dexmedetomidine and lidocaine combination (DL) 
versus propofol and fentanyl combination (PF) during 
ERCP procedure. In our study there was no event of 
drug adverse or cardiovascular complication observed 
in both regimens. 
The case of oxygen desaturation (SpO2 <90%) 
was observed in PF groups after the loading dose at 5 
to 35 minutes during ERCP procedure. While, it was 
absent in DL group and no cases in this group 
presented oxygen desaturation (SpO2 <90%). There is 
a significant difference in the oxygen saturation 
(SpO2) level between the two groups in the 15, 20 
and 25 minute of ERCP process (P<0.05). Patients in 
DL group significantly showed more stability of 
SpO2. So, the results demonstrate that combination of 
DL gives more respiratory safety than propofol with 
fentanyl combination (P<0.01). In contrast to Muller 
et al. studies which reported, no statistical difference 
in SpO2 between the dexmedetomidine as the sole 
anesthetic agent and propofol group (14). There were 
no significant differences in MAP, HR values at all-
time points between the two groups (P>0.05). 
Recovery times were significantly longer in the DL 
group. Nausea and Vomiting (PONV) were observed 
in one patient (3.2%) in group PF, while it was absent 
in DL group, this result was consistent with previous 
study (24).  
The most important result from this study was 
the persistence of oxygen saturation (SpO2) in 
patients, who received dexmedetomidine and 
lidocaine combination (DL). No reported of oxygen 
desaturation (SpO2<90%) in DL group and more 
stability of SpO2 during ERCP procedure in this 
group is very important because most patients who 
underwent ERCP are generally elderly and require 
sedation while in the prone position. This factor may 
be expected to prevent the risk of arterial hypoxemia 
(25). Arterial hypoxemia indicate impending 
respiratory failure or by itself may result in adverse 
physiological effects including acidosis, 
hyperkalemia, release of circulating catecholamines, 
myocardial excitation or depression, arrhythmias, 
arterial hypertension or hypotension, headache, 
intracranial hypertension, and agitation or narcosis 
(26-28).The limitation of this study was we don’t 
measure respiratory rate, as the prone position makes 
it difficult to accurately count respiratory rate both 
artificially and automatically. So, the effect on 
respiratory function was judged only by SpO2, which 
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may lead to missing subclinical respiratory 
depression. 
Conclusion 
Dexmedetomidine with lidocaine is a new 
combination that has been used in sedation or 
analgesia for short procedures as ERCP for first time 
in this study. Compared to other drugs and 
combinations, it provides similar effects; no event of 
hypotension or bradycardia but it has an added benefit 
with less number of postoperative side effects such as 
nausea and vomiting (PONV) and the most important 
result from this study was DL combination as total 
intravenous anesthesia (TIVA) during ERCP not only 
did not reported any oxygen desaturation 
(SpO2<90%) but also showed better stability of 
oxygen saturation (SpO2). 
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